A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Case report. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

By Itskovitz-Eldor J  

Human Reproduction, Vol. 13, Iss. 2, 1998-02 ,pp. : 294-295

Oxford University Press

Access to resources Recommend Favorite

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone

By Messinis IE  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2415-2420

Oxford University Press

Access to resources Recommend Favorite

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation

By Out HJ  

Human Reproduction, Vol. 14, Iss. 3, 1999-03 ,pp. : 622-627

Oxford University Press

Access to resources Recommend Favorite

Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial

By Kamischke A  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 596-603

Oxford University Press

Access to resources Recommend Favorite